Shepherd, Finkelman, Miller & Shah, LLP
Shepherd, Finkelman, Miller & Shah, LLP
866-540-5505 877-891-9880

Dedicated Client Advocacy

Posts tagged "product hopping"

Allergan, Senju, & Kyorin To Pay $9 Million to Settle Product Hopping Suit

On February 16, 2018, Allergan Inc. ("Allergan"), Senju Pharmaceutical Co. Ltd., and Kyorin Pharmaceutical Co. Ltd. (collectively, "Defendants") announced a proposed settlement in which they will pay Hartig Drug Co. Inc. ("Plaintiff") $9 million to end a class action over alleged "product hopping" related to eye care products, Zymar and Zymaxid. Product hopping is a term used to describe the practice of pharmaceutical companies making modest drug reformulations that offer little or no therapeutic advantages in an effort to obstruct generic competitors and preserve monopoly profits on a patented drug. In 2012, the Federal Trade Commission filed an amicus brief stating that product hopping undermines state and federal laws that encourage generic competition and explained that the conduct can be the basis for an antitrust lawsuit.[1]